← FDA DRUG APPROVALS

FDA ANDA · ANDA209742

BOSENTAN

Sponsor: AMNEAL PHARMS CO

APPLICATION
ANDA209742
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-26
LATEST ACTION
2026-07-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

BOSENTANDiscontinued
BOSENTAN 125MG · TABLET · ORAL
BOSENTANDiscontinued
BOSENTAN 62.5MG · TABLET · ORAL

Approval history

2026-07-23Labeling · Supplement 15 · standardAP
2026-07-23Labeling · Supplement 13 · standardAP
2026-03-03REMS · Supplement 16AP
2025-11-05REMS · Supplement 12AP
2025-02-21REMS · Supplement 10AP
2024-09-17REMS · Supplement 9AP
2024-07-11Labeling · Supplement 7 · standardAP
2024-07-11Labeling · Supplement 6 · standardAP
2022-04-29REMS · Supplement 5AP
2019-11-04Labeling · Supplement 2 · standardAP
2019-04-26UNKNOWN · Original · standardREMSAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →